383 related articles for article (PubMed ID: 23620577)
1. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.
Experts in Chronic Myeloid Leukemia
Blood; 2013 May; 121(22):4439-42. PubMed ID: 23620577
[TBL] [Abstract][Full Text] [Related]
2. Pricing Cancer Drugs: When Does Pricing Become Profiteering?
Kushnick HL
AMA J Ethics; 2015 Aug; 17(8):750-3. PubMed ID: 26270874
[No Abstract] [Full Text] [Related]
3. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.
Padula WV; Larson RA; Dusetzina SB; Apperley JF; Hehlmann R; Baccarani M; Eigendorff E; Guilhot J; Guilhot F; Hehlmann R; Mahon FX; Martinelli G; Mayer J; Müller MC; Niederwieser D; Saussele S; Schiffer CA; Silver RT; Simonsson B; Conti RM
J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26944912
[TBL] [Abstract][Full Text] [Related]
4. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
Shih YT; Cortes JE; Kantarjian HM
Lancet Haematol; 2019 Aug; 6(8):e398-e408. PubMed ID: 31208943
[TBL] [Abstract][Full Text] [Related]
5. Generics in chronic myeloid leukemia: current arguments for and against and the established evidence.
Soysal T; Eskazan AE; Ar MC
Expert Rev Hematol; 2014 Dec; 7(6):697-9. PubMed ID: 25292262
[TBL] [Abstract][Full Text] [Related]
6. The value of open access and a patient centric approach to oral oncolytic utilization in the treatment of Chronic Myelogenous Leukemia: A U.S. perspective.
Das L; Gitlin M; Siegartel LR; Makenbaeva D
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):133-140. PubMed ID: 28287008
[TBL] [Abstract][Full Text] [Related]
7. Indian patients go to court over cancer drug.
Murdur G
BMJ; 2004 Aug; 329(7463):419. PubMed ID: 15321889
[No Abstract] [Full Text] [Related]
8. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model application.
Ghatnekar O; Hjalte F; Taylor M
Acta Oncol; 2010 Aug; 49(6):851-8. PubMed ID: 20615173
[TBL] [Abstract][Full Text] [Related]
9. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
Lejniece S; Udre I; Rivkina A
Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
[TBL] [Abstract][Full Text] [Related]
10. Having "Skin in the Game" and Allowing Cross-Border Importation of Drugs to Lower High Prices of Cancer Drugs.
Kantarjian H; Mathisen MS; Lipton JH
JAMA Oncol; 2015 Sep; 1(6):729-30. PubMed ID: 26182331
[No Abstract] [Full Text] [Related]
11. Pricing increases for cancer drugs sparks investigation.
Venkatesan P
Lancet Oncol; 2017 Jul; 18(7):e372. PubMed ID: 28552213
[No Abstract] [Full Text] [Related]
12. Makers of anticancer drugs are "profiteering," say 100 specialists from around the world.
Laurance J
BMJ; 2013 Apr; 346():f2810. PubMed ID: 23633224
[No Abstract] [Full Text] [Related]
13. Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia.
Nguyen JT; Cole AL; Leech AA; Wood WA; Dusetzina SB
Value Health; 2020 Oct; 23(10):1292-1299. PubMed ID: 33032772
[TBL] [Abstract][Full Text] [Related]
14. [Economic burden for patients with chronic myelogenous leukemia--healthcare economics and medical governance of cancer].
Kodama Y; Kami M
Gan To Kagaku Ryoho; 2010 Apr; 37(4):577-81. PubMed ID: 20414010
[TBL] [Abstract][Full Text] [Related]
15. How we will treat chronic myeloid leukemia in 2016.
Talati C; Ontiveros EP; Griffiths EA; Wang ES; Wetzler M
Blood Rev; 2015 Mar; 29(2):137-42. PubMed ID: 25555325
[TBL] [Abstract][Full Text] [Related]
16. Sticker shock.
Nat Med; 2013 Jun; 19(6):653. PubMed ID: 23744133
[TBL] [Abstract][Full Text] [Related]
17. Bcr-Abl tyrosine kinase inhibitors: a patent review.
Desogus A; Schenone S; Brullo C; Tintori C; Musumeci F
Expert Opin Ther Pat; 2015 Apr; 25(4):397-412. PubMed ID: 25656651
[TBL] [Abstract][Full Text] [Related]
18. Generic Price Competition For Specialty Drugs: Too Little, Too Late?
Cole AL; Dusetzina SB
Health Aff (Millwood); 2018 May; 37(5):738-742. PubMed ID: 29733710
[TBL] [Abstract][Full Text] [Related]
19. [Chronic myeloid leukemia – a model disease for targeted therapy].
Richter J; Stenke L
Lakartidningen; 2017 Sep; 114():. PubMed ID: 28949401
[TBL] [Abstract][Full Text] [Related]
20. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
Gambacorti-Passerini C; Piazza R
JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011
[No Abstract] [Full Text] [Related]
[Next] [New Search]
